Bukwang announces patent registration of SOL-804 in 32 countries
R&D NEWS
Bukwang Announces the result of SOL-804’s Phase 1 clinical trial
Bukwang Announces Completion of SOL-804’s Phase 1 clinical trial
Bukwang expanded the partnership of ‘Aprovel and CoAprovel’ to General Hospitals
Bukwang initiates dosing of SOL-804 in the phase 1 study


Bukwang received approval of a new drug ‘Ozanex cream’ , a topical antibiotic
Bukwang registered a composition patent for SOL-804 in the U.S.
Approval of phase 1 clinical study for anticancer drug, SOL-804
Contera Pharma, a subsidiary of Bukwang, has partnership with Abzu
Bukwang concluded the patient recruitment for the clinical trial of covid-19 treatment
Bukwang confirmed Levovir showed tendency of reducing virus from Phase 2 clinical trial topline data
Bukwang initiates dosing of JM-010 in the US phase 2 study
Bukwang Pharmaceutical increased the number of patients for the clinical trial of covid-19 treatment
Bukwang received US FDA approval for phase 2 clinical study IND of Levovir, as a COVID-19 treatment.
Bukwang concluded the 60 patients recruitment for the clinical trial of covid-19 treatment
Bukwang registered composition patent for SOL-804 in Europe
Contera Pharma, subsidiary of Bukwang, elected specialists in global CNS area
ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing
Bukwang has been granted a patent for its antiviral agent, Levovir, as COVID-19 treatment.
Dyna Therapeutics, subsidiary of Bukwang, registered patent of anticancer drug SOL-804 in Japan
Contera Pharma, subsidiary of Bukwang, raised 51 billion KRW in Series B financing round
Bukwang exports hipnotic-sedative emergency drug for COVID-19 related treatment
Bukwang’s antiviral drug, Levovir®, confirms antiviral effect against coronavirus


Bukwang Initiates Exportation of its In-House-Developed Drug, DEXIDⓇ to Southeast Asia
ProteKt Therapeutics Raises $3.6 Million in Post-incubation Financing


ASLAN PHARMACEUTICALS AND BUKWANG PHARMACEUTICAL ESTABLISH A JOINT VENTURE, JAGUAHR THERAPEUTICS, TO

Contera Pharma, a subsidiary of Bukwang Pharmaceutical, attracts investment from Medici Investment

University of Dundee partners with Bukwang Pharmaceutical Company to tackle new drug treatment for P

BNO BIO, a joint company by Bukwang and OCI, invests in a bio-venture that develop a technology in e
Bukwang Announced commencement of Phase 2 Clinical Study of JM-010 in major European countries
Bukwang Announces Completion of MLR-1023’s Phase 2b clinical trial
Bukwang Announces completion of dosing of MLR-1023’s phase 2b study.
Bukwang Announces approval of Clinical Trial Application by European authority to initiate Phase 2 s
Bukwang Pharmaceutical Co., Ltd. entered into a license transfer agreement of Rivoceranib for 40 bil
Bukwang Pharmaceutical Co., Ltd. completed global phase 2b study of MLR-1023, novel candidate for ty
Bukwang Pharmaceutical Co., Ltd. expects to complete patients enrollment for global phase 2b study o
Bukwang-OCI, Pharmaceutical and Bio industry Business alliance
Bukwang Pharmaceuticals, began to expand the lineup of anticancer drugs - Development of drugs for
Bukwang Pharm, income from AurKa Pharma investment - Upfront approx. 6 billion won, additional miles
Bukwang initiates phase 3 study with lurasidone HCl for patients with Schizophrenia
Listening to shareholders’ opinions and answering to inquiries, Bukwang gained shareholders’ approva
Bukwang pushes on its export of DEXID, a self-developed incrementally modified drug, to Southeast As
Bukwang Pharmaceutical Co., Ltd.(“Bukwang”) registered patents on a therapeutic candidate for Levodo
Bukwang Pharmaceutical Co., Ltd. a novel candidate for type 2 diabetes, MLR-1023 is undergoing globa
Acer Therapeutics, in which Bukwang is investing, is to go public - through merger with Opexa Therap
Bukwang announces the conclusion of an exclusive license agreement with Sumitomo Dainippon Pharma on
Bukwang Pharmaceutical Co., Ltd. received 5.8 B KRW from its investment in CoLucid, an American pha
Bukwang Pharmaceutical Co., Ltd. LID treatment ‘JM-010’ is approved for Orphan Drug Designation

Bukwang launched cosmetic products to target Dermocosmetic industry Importing ‘Repavar’ products fro
Bukwang Pharmaceutical Co., Ltd, submitted Phase 2b IND for new diabetic drug candidate, MLR-1023